Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.34 |
| ▸ | PTPRA | P18433 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164383 | 0.83 | TLR8 (0.33) | NLRP3PTPRATLR7KCNA5KCNJ5 | |
| SCHEMBL27345681 | 0.80 | ADORA2A (0.33) | ADORA2ATRPA1 | |
| SCHEMBL15255480 | 0.76 | LMNA (0.35) | NLRP3PTPRALMNAKCNA5MEN1 | |
| SCHEMBL29124570 | 0.75 | CSNK1E (0.36) | NLRP3TRPA1 | |
| SCHEMBL28643131 | 0.75 | PTPRA (0.56) | PTPRALMNATLR7 | |
| SCHEMBL9006913 | 0.72 | APEX1 (0.38) | PTPRALMNATSHR | |
| SCHEMBL9035682 | 0.71 | KDM4E (0.30) | — | |
| SCHEMBL2399051 | 0.71 | CYP1A2 (0.44) | NLRP3PTPRALMNAMEN1TSHR | |
| SCHEMBL20279052 | 0.71 | GRIN2D (0.30) | — | |
| SCHEMBL2948062 | 0.70 | KDM4E (0.39) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK1A1, CSNK1A1L, CSNK1E | ADORA2A 3026/4885NLRP3 3719/4885PTPRA 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.